Exelixis Company Profile

02:56 EST 20th November 2017 | BioPortfolio

A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful impact on the lives of patients living with cancer. We are advancing an ambitious and pragmatic approach to drug development, to develop first-in-class and best-in-class therapies that will transform the treatment of cancer. We are transforming the challenges of our industry into opportunities for success by thinking larger, moving faster and charting our own course to our goal. Today we are a development-stage biotechnology company with an uncommonly rich pipeline of twelve compounds in clinical development with many more advancing to the clinic. As we look toward the future, we are building a portfolio of targeted compounds that modulate the activity of multiple disease-related pathways to achieve superior disease control and patient outcomes. Leveraging the Power of Our Platform We believe that the next generation of cancer therapies requires innovation in every part of our research, development and business organizations. At Exelixis, this means pursuing an uncommon approach to research and development, one that combines critical mass, speed, and unique approaches to create significant momentum toward our goals. With a library of more than 4 million compounds, we are able to rapidly identify high-quality leads for new drugs. Our extensive abilities in structure-based design and our approaches to pharmacodynamics and pharmacokinetics enable us to move these leads quickly forward. These capabilities are a resource that will enable us to file at least three investigational new drug applications (IND) each year for the foreseeable future. Even with an extensive and vigorous selection process to assure high-quality, we retained our speed, filing twleve INDs in the past three years. The strength and efficiency of our selection, screening and development processes provide a steady flow of promising product candidates. With so many opportunities, we believe that we have the ability to select only those compounds for which the data demonstrate clear first-in-class and best-in-class. This power is combined with a disciplined, pragmatic approach to managing our pipeline based on data and real medical need. Building the Momentum Toward or Goal We believe our commitment to significantly invest in preclinical development provides a more solid foundation on which to build new treatments for cancer. We believe the return on this investment will come in the form of higher clinical success rates and funding and partnership terms that allow us to retain increasing equity in the long-term value of our pipeline. Our strategic partnerships with GlaxoSmithKline, Bristol-Myers Squibb Company and Symphony Capital exemplify how our innovative approach to drug development is enabling us to create value for our shareholders and patients. Based in South San Francisco, California, Exelixis has over 550 dedicated employees who share a commitment to making a positive difference in the lives of patients with cancer and other serious diseases.


210 East Grand Avenue
P.O. Box 511
South San Francisco
United States of America


Phone: (650) 837-7000
Fax: (650) 837-8300

News Articles [84 Associated News Articles listed on BioPortfolio]

Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical ...

Investors Contact:Exelixis, Inc.Susan Hubbard, 650-837-8194EVP, Public Affairs and Investor Relationsshubbard@exelixis.comorMedia Contact:For Exelixis, Inc.Hal Mackins, 415...

Company Spotlight: Exelixis

Shares of Exelixis Inc. (EXEL) are up an impressive 78% year-date compared to 19% gain by the iShares NASDAQ Biotechnology Index during the same period.

Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib ...

– Exelixis and Ipsen to host investor and media webcast from Madrid to discuss the data on Sunday, September 10 starting at 6:45 p.m. CEST – Read more...

Ipsen and Exelixis set for huge Cabometyx gains

Cabometyx (cabozantinib), a drug developed by US biotech Exelixis and French drugmaker Ipsen, is fast…

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo in Combination with CABOMETYX™ or Opdivo and Yervoy in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

- First phase 3 trial in a global clinical development program to explore the combination of these agents - - Exelixis, Bristol-Myers Squibb and Ipsen to co-fund this trial - Exelixis, Inc. (NASDA...

Exelixis clears debt, turning eye to future growth

Boosted by growing revenues from its kidney cancer drug Cabometyx, Exelixis is wiping its debt clean and betting it can fund growth from operations. 

Exelixis and Genentech hammer out new deal terms

After a year of arbitration, Exelixis and Genentech shake hands on a revised deal.

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

But it's been a really great year for Immunogen The past is the past, though. Which of these cancer-focused biotech stocks is the better choice for investors now? Here's how Exelixis and Immun...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [6 Associated Companies listed on BioPortfolio]

Exelixis Inc.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercializat...

Exelixis, Inc.

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other s...

Exelixis, Inc. and Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....


A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful impact on the lives of patients living with cancer. We are advancing an ambitious and pragmatic approach to drug de...

ARTEMIS Pharmaceuticals

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in ve...

More Information about "Exelixis" on BioPortfolio

We have published hundreds of Exelixis news stories on BioPortfolio along with dozens of Exelixis Clinical Trials and PubMed Articles about Exelixis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Exelixis Companies in our database. You can also find out about relevant Exelixis Drugs and Medications on this site too.

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record